GNI Group

GNI Group is a Tokyo, Japan-based biopharmaceutical company that develops innovative drugs and medical devices targeting unmet needs in fibrosis, oncology, orthopedics, and medical aesthetics. The publicly traded enterprise operates under the ticker TSE: 2160 and manages three core strategic holdings across the global pharmaceutical, biotechnology, and medtech sectors. Its synergistic operations include entities such as OsDerma Medical and Shanghai Genomics, alongside a recent reverse merger transaction involving the NASDAQ-listed company PULM. The organization's executive leadership team includes President and Chief Executive Officer Ying Luo, Chairman Thomas Eastling, and board member Ryosuke Matsui, who co-established a global medical device investment fund in 2021. The broader corporate structure traces its origins to the establishment of key affiliate Shanghai Genomics, which was co-founded in 2001 by Wu Jun prior to the parent group's public listing in 2007.